purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation zts earnings call period ending december image source motley fool zoetis zts q earnings callfeb etcontents prepared remark question answer call participant prepared remark operatorwelcome fourthquarter fullyear financial result conference call webcast zoetis hosting call today steve frank vice president investor relation zoetis presentation material additional financial table currently posted investor relation section zoetiscom presentation slide managed viewer forwarded automatically addition replay call available approximately two hour conclusion call via dialin investor relation section zoetiscom operator instruction pleasure turn floor steve frank steve may beginsteve frank vice president investor relation thank operator good morning everyone welcome zoetis fourthquarter fullyear earnings call joined today kristin peck chief executive officer wetteny joseph chief financial officer begin remind slide presented call available investor relation section website remark today include forwardlooking statement actual result could differ materially projection list description certain factor could cause result differ refer forwardlooking statement today press release sec filing including limited annual report form k report form q remark today also include reference certain financial measure prepared accordance generally accepted accounting principle yous gaap reconciliation nongaap financial measure directly comparable yousshould invest zoetis right buy stock zoetis consider motley fool stock advisor analyst team identified believe best stock investor buy zoetis one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return february gaap measure included financial table accompany earnings press release company k filing dated today tuesday february th also cite operational result exclude impact foreign exchange turn call kristin kristin peck chief executive officer thank steve welcome everyone fourthquarter fullyear earnings call today reported strong fullyear result driven success diverse portfolio across market specie gamechanging innovation outstanding commitment purposedriven colleague delivered operational revenue growth growing faster industry propelled steady demand innovative product enable customer animal care thrive ongoing momentum monoclonal antibody osteoarthritis oa pain saw segment growth yous operational growth internationally companion animal portfolio remains key growth driver operationally saw return growth livestock portfolio operationally continue operate environment global uncertainty diversity across market specie therapeutic area sustained performance demonstrating animal health durable essential growing industry track record innovation pioneering breakthrough product life cycle enhancement solidified position industry leader consistently growing market enabled u create marketleading franchise follow trend make market launch librela solensia first two injectable monoclonal antibody alleviation osteoarthritis fundamentally improving quality life dog cat strengthening humananimal bond today librela remains selling oa pain product europe investor day last may jpmorgan healthcare conference shared pain franchise could peak sale exceeding billion excited librelas performance since yous launch october reaffirms view due high clinic penetration activated directtoconsumer dtc effort faster product history expect provide tailwind commercial growth similarly solensia also well received strong clinic penetration around world increased opportunity generate awareness oa pain map within dermatology franchise established trusted partner veterinarian nearly decade impressive growth still believe room expand market increasing pet owner awareness itch medical condition requires treatment improve compliance opportunity address even unmet need underpins optimism remain confident sustain growth thanks differentiated product like cytopoint apoquel chewable first chewable treatment control allergic itch inflammation dog parasiticide portfolio particularly simparica trio remains key growth driver even face increasing competition continued success highlight strategic execution label strength efficacy product performance across key product franchise reinforces marketleading position also better innovation consistently meet evolving demand veterinary medicine begin stay disciplined adaptable evolving macroeconomic geopolitical backdrop around world focus executing plan continuing grow faster market two durable global trend give u confidence future growth powerful humananimal bond world growing need sustainable supply animal protein commitment operational excellence ensures ready scale meet demand navigate unforeseen challenge delivering shareholder value looking ahead committed track record value creation abovemarket performance dedication innovation remains cornerstone marketleading position consistently demonstrated agility outpacing market bring groundbreaking solution meet exceed customer expectation continue leverage advantage guiding range operational revenue growth adjusted net income growth range operationally reflects ongoing investment rd supply chain commercial excellence cultivate new market drive growth create value heard say time time confident strategy portfolio pipeline capability deliver value shareholder customer performing market focus position u well navigate potential challenge capitalize emerging opportunity closing continue relentless pursuit exceed customer expectation invest advancing capability differentiate zoetis look could excited future key growth driver continue showcase commitment nurturing world humankind advancing care animal ongoing innovation expand market reaffirm bestinclass product portfolio defend position amid competition want reiterate four tenet value proposition discussed investor day grow revenue faster market invest innovation growth capability commit growing adjusted net income faster revenue return excess capital shareholder need demand improve quality life animal zoetis continue leading way setting standard performance growth core vision trusted valued animal health company shaping future animal care innovation customer obsession purposedriven colleague thank let hand wetteny wettenywetteny joseph chief financial officer thank kristin good morning everyone kristen mentioned strong year revenue billion adjusted net income billion fullyear revenue near top end guidance range adjusted net income slightly guidance range primarily due impact foreign exchange well impairment charge related prior acquisition revenue growth broad strong growth across yous international segment companion animal lifestyle portfolio due price volume fullyear revenue grew reported basis operationally adjusted net income increasing reported operational basis operational revenue growth price volume volume growth driven primarily new product including monoclonal body oa pain librela solensia well key dermatology product simparica trio segment basis yous business posted billion revenue growing year international segment reported revenue billion operational growth full year additionally china represents le global revenue ongoing economic weakness continues impact business represented percentage point drag total company operational revenue growth year entirely volume full year growth driven continued demand innovative companion animal portfolio grew operationally lifestyle portfolio also strong year operational growth performance companion animal led oa pain map posted million global revenue year growth came first wave european market well impact new launch market including yous continue see penetration pain map grow within vet clinic high level satisfaction among vet pet owner key dermatology product generated billion sale globally posting strong growth year operational basis simparica trio contributed global revenue million representing growth operationally despite distributor inventory headwind q aggressive competitive promotion much year companion animal diagnostics portfolio recorded million revenue grew operationally growth contribution yous international lifestyle portfolio strong year operational revenue growth driven price volume moving q financial result another strong quarter closed q revenue billion representing increase reported operational basis posting third consecutive quarter least operational revenue growth despite tough comparative particularly yous companion animal adjusted net income million increase reported operational basis operational revenue growth price volume volume growth assisted growth new product decline inline product volume key dermatology product flat quarter segment basis yous business posted billion revenue growing quarter international segment reported revenue million operational growth quarter companion animal portfolio main driver revenue growth quarter growing operationally livestock also contributed operational growth saw doubledigit companion animal growth yous international segment driven innovative product oa pain map primary driver growth posting million combined revenue quarter global growth came primarily impact new launch market bolstered q launch librela yous simparica trio generated million globally quarter representing growth operationally price primary driver growth quarter followed volume growth driven expanded dtc advertising support globally well increased field force focus key dermatology product generated million sale globally posting growth operational basis companion animal diagnostics portfolio reported revenue million grew operationally growth contribution yous international lifestyle product ended year strong note growth operationally growing yous international segment growth driven equally price grew despite headwind draxxin price decrease well volume growth synovex expanded label claim moving revenue growth segment quarter yous revenue billion quarter growing companion animal sale growing livestock sale growing companion animal posted doubledigit growth quarter bolstered full launch librela start quarter facing tough comparative quarter promotional activity heavierthannormal pre price buyin end last year yous vet clinic visit flat quarter flat year continue see solid clinic revenue revenue per visit growth quarter year yous companion animal revenue growth continues outpace veterinary clinic revenue growth due part innovative therapeutic well strong presence retail channel moving product performance growth yous driven pay map simparica trio key dermatology portfolio combined pain map posted million yous sale q moved full launch librela yous early fourth quarter pleased result field force able drive thus far librela posted million yous sale quarter higher end initial expectation important note leveraging distribution pain map significant clinic stocking impact first month launch seen higherthanexpected penetration reorder rate end year well rapid patient share growth canine pain category solensia sale million q yous seen marked increase feline vet visit feline revenue growth clinic yous feline oa patient simparica trio posted yous sale million quarter growing growth driven primarily price ran promotion q following q supply challenge advance expected competitor launch early second quarter competition trip combination space continue see patient share growth simparica trio remain confident ability compete grow space strength label retail channel presence strong corporate specialty relationship significant advantage first market key dermatology product sale yous million quarter growing cytopoint sale continue drive growth price volume vet pet owner referring injectable method administration simparica franchise growth driven better net price realization lower volume due promotional activity end last year yous companion animal diagnostics portfolio posted growth quarter yous livestock grew quarter primarily driven growth poultry result favorable rotation back certain medicated feed additive extended use zoamix well share gain due competitor supply constraint sale swine cattle product increased quarter primarily result increased supply vaccine limited quarter prior year moving international segment revenue quarter grew reported basis excluding impact foreign exchange international companion animal grew operationally lifestyle grew operational china represented drag international segment operational revenue growth quarter higher sale companion animal product led pain map key dermatology product small animal parasiticides portfolio growth oa pain product equally driven full focus dtc awareness campaign early launch european market well continued uptake market launched earlier year librela sale million international operational growth quarter solensia sale million internationally quarter growing operationally international key dermatology portfolio contributed million revenue posting growth quarter operational basis continue see benefit apoquel dtc awareness campaign across several international market conversion apoquel chewable positive growth cytopoint continues benefit higher rate conversion apoquel overall market growth international small animal parasiticides portfolio grew operationally driven simparica franchise simparica posting million revenue growing operational basis quarter driven primarily price strong price season demand generation emerging market simparica trio contributed million internationally growing operationally driven high peak season sale australia continued uptake europe driven key account penetration field force effectiveness growth partially offset operational decline revolution franchise generates high proportion sale china tough comparative quarter due return supply q well ongoing impact current economic condition continuing onto international livestock grew operationally driven primarily price increase specie especially high inflationary market poultry portfolio also benefited favorable mfa rotation certain market china unfavorable impact international livestock sale quarter particularly swine portfolio moving rest pl quarter adjusted gross margin decreased basis point reported basis compared prior year operational basis adjusted gross margin decreased basis point resulting primarily higher manufacturing cost partially offset price increase lower freight cost adjusted operating expense increased operationally driven primarily higher sga expense operationally primarily due higher competitionrelated expense well charitable contribution related funding zoetis foundation rd expense grew operational basis driven higher compensationrelated expense well portfolio progression key pipeline project finally income deduction higher quarter due impairment charge related acquisition adjusted effective tax rate quarter decrease basis point primarily due higher net dispute tax benefit quarter higher benefit yous related foreignderived intangible income favorable jurisdictional mix earnings adjusted net income grew operationally adjusted diluted eps grew operationally quarter capital expenditure fourth quarter million full year capital expenditure million lastly continue return excess capital shareholder year returned approximately billion shareholder combination share repurchase dividend december announced annual dividend increase continuing commitment grow dividend faster growth adjusted net income moving guidance full year please note guidance reflects foreign exchange rate late january expecting foreign exchange incredible impact growth versus prior year net revenue expect foreign exchange negatively impact growth basis point impact pronounced early year decreasing later year adjusted net income expect fx negatively impact growth basis point significant unfavorable impact first half year transitioning slight favorability second half year reminder actively forecast fx estimate assume rate remain late january projecting revenue billion billion representing range operational growth growth across price volume expect companion animal primary growth driver expected impact yous launch librela expect see robust growth pain map yous internationally current clinic penetration level librela yous exceeding expectation kristin mentioned launched dtc effort ahead schedule drive increased pet owner awareness even expectation competitive entrant anticipate mid high singledigit growth simparica trio key dermatology portfolio livestock exceeded expectation growth year benefited several tailwind including improvement supply certain market well competitive stock outlook upcoming year optimistic enter expect growth rate normalize line lifestyle industry growth would like briefly touch upon key assumption underpin expectation revenue growth companion animal projecting significant change current vet clinic trend expect yous visit grow flat expect see growth therapeutic visit aided impact pain product animal parasiticides continue expect meaningful growth simparica trio expect new entrant help continue drive conversion topicals collar triple combination animal parasiticides space market leader key dermatology product prepared competition confident ability defend grow share three differentiated dermatology product strength customer relationship expertise gained almost year space lastly assuming change current economic situation china expect headwind growth especially first half situation worsened course moving rest pl adjusted cost sale percentage revenue expected approximately continue make investment ensure support expected future growth portfolio especially monoclonal antibody investment driving shortterm margin impact lower state utilization offset price increase favorable product mix adjusted sga expense year expected billion billion increase focused supporting primary driver revenue growth adjusted rd expense expected million million spend driven advancement key pipeline project well higher competitionrelated expense adjusted interest expense income deduction expected approximately million significantly higher prior year growth negatively impacted nonrecurring royalty settlement income reflected q well impact lower interest income adjusted effective tax rate expected range adjusted net income expected range billion billion representing operational growth guidance reflects value proposition growing revenue line faster market growing adjusted net income faster revenue expect adjusted diluted eps range reported diluted eps range finally anticipating capital expenditure range million million level remain elevated compared historical spend level continue make investment support future growth summarize another strong year even distributor inventory headwind entering year challenging economic environment especially china outperformed market continue grow share even space face new competition remain confident ability expand existing market create new one future move guidance highlight ability grow faster market driven innovative product portfolio multiple source growth well ability grow bottom line faster pipeline making meaningful investment future returning significant excess capital shareholder hand thing operator open line question operator question answer operatorthank operator instruction take first question erin wright morgan stanley please go aheaderin wright morgan stanley analyst great thanks taking question talk little bit reorder rate feedback expectation around librela yous stocking dynamic think quarter quarter bigger picture question margin profitability moving factor fx rampup librela weigh margin talk little bit potential margin leverage could see across business expand fastergrowing highermargin category beyond could describe little bit longerterm margin leverage thankskristin peck chief executive officer thank erin take first question librela let wetteny take second question yeah pleased librela first full quarter launch q saw million quarter million year including early experience trial really achieved penetration ahead schedule mentioned prepared remark given penetration high actually began dtc ahead expecting reorder rate coming exactly expected line expectation make u really confident go year looking question kind stocking inventory build saw click hard give firm number somewhere quarter third would say overall stocking look selling pain product europe doubt yous well quite pleased certainly ahead plan penetration look directtoconsumer advertising investment already started late last year q drive growth product yous let wetteny take second questionwetteny joseph chief financial officer yeah sure look looking margin yes indeed moving factor think beyond librela said investor day look monoclonal antibody peak particularly ramp production capacity built make sure confident able take advantage demand started dilutive overall company average example go librela becomes accretive overall margin still whether would consider innovative companion animal product exit beyond becomes line innovative companion animal product overall beyond give specific guidance term expect think look continue expect companion animal outpace growth livestock mix continue favorable u get higher level production monoclonal antibody also accretive overall margin positioned able leverage sga base well translate margin expansion pl time demonstrated afraid make right investment behind product behind key franchise see investment rd saw guide implies rd continue grow faster revenue well investment slightly offset positioned continue expandoperatorthank take next question michael ryskin bank america please go aheadmike ryskin bank america merrill lynch analyst great thanks taking question guy first want touch margin maybe look like guiding back analogue math guiding bps margin expansion also finish lower would expected think q especially came significantly lower called headwind call term fx call timing contribution zoetis charitable foundation way could kind back give u sort cleaner number margin maybe onetime headwind would impact give u better sense underlying margin underlying eps second question following librela believe actually quantified target want given q major focus point something like million million librela reasonable especially yous ous side heard concern maybe coming europe seems like librela sort little bit flat last couple quarter international market color going internationally thankswetteny joseph chief financial officer yes sure mike let take see kristin want add take look margin indeed guiding basis point expansion margin keep mind look ended q basis point margin impact fx talking roughly basis point consider manufacturing cost little bit mix looking mix clearly really strong quite frankly strong year livestock actually national sale meeting livestock lifestyle team utah look great year expect lifestyle continue grow go clearly ended stronger end created little bit mix yes well librela outperforming expectation exiting year also said bit dilutive look mix manufacturing cost still talking basis point headwind exiting impact coming fx basis point item referenced prepared commentary respect impact quarter ended fx impact finish take look fx clearly nonoperational factor nonrecurring item like impairment charge prior acquisition two item headwind quarter fourth quarter really vast majority saw impacting u course forecast fx bake guidance essentially would happen assume fx rate stay end january constant basis would expect expand margin really consistent approached forecasting past sit guess fx going throughout year impact either favorable unfavorable depending go part question want maybe talk little bit librela expect librela clearly think deliver operational growth revenue price pretty significant factor continue expect running price historic level point perhaps slightly saw librela yous launch clearly going significant factor certainly million quarter q pleased see see quarter third initial stocking model term would translate still early stage launch pleased seeing far discussed already international could pleased seeing look international fourth quarter still growth look base market launched beginning year new market driving another bit growth another million contribution new market addition yous million think really take account launching market europe stocking happens quarter quarter launch factor focus market already launched talking growth quarter consistent last quarter give take going pleased seeing international marketsmike ryskin bank america merrill lynch analyst greatoperatorwell move next jon block stifel please go aheadjon block stifel financial corp analyst ok thanks guy good morning wendy revenue cadence year call got sort easier q comp also noting acute china headwind first half think sort look twoyear stack basis guidance full year maybe gm little bit thinking sga expense despite investment kristin called accelerated dtc sga little bit lower head maybe talk item seeing seems like low midsingledigit sga growth year year know blunted fx finally sorry librela due stocking still expect librela yous q q absorbs stocking thanks guyswetteny joseph chief financial officer look take cadence point first see kristin want add term librela expectation look look sitting would expect roughly balanced cadence across year let u take look q specific point raised question john look q certainly look companion animal yous easier comp destocking first quarter last year clearly something look see easier comp come time growth quarter livestock q think look balance complete balance lifestyle growth yous well international china clearly started deteriorate term economic condition throughout year becomes heavier would say headwind coming q well condition weather condition australia etc impact think balance last point make librela clearly pleased exit q enter going continue contribute go year q q would q therefore contribution novella accelerates year much relative speaking q take consideration actually see roughly balanced year make reference fx reported basis taking look fx rate couple week ago heavier impact term revenue bottom line fx de facto hopefully provide prepared commentary helpful piece think think operational base growth mean exit year momentum exited q q looking yous companion animal think q going higher q librela perspective think factor quarter third impact coming stock million million even flat mean grow million million going q call exactly right would say pleased product performing still early stage launchoperatorthank take next question david westenberg piper sandler please go aheaddave westenberg piper sandler analyst hi thank taking question last year saw discounting front next gaurd combo launch anticipate might similar competitive dynamic front elancos quattro launch thinking consideration gross margin second one dtc effort librela think dc allowed europe talk maybe learning learned europe term marketing might apply specifically around communication vet obviously one understands superior safety profile monoclonal antibody maybe messaging come thank youkristin peck chief executive officer sure start one wetteny certainly build mean want first underscore strong q trio growth quarter competition year overall trio grew pleased guided wetteny mentioned earlier expecting mid high singledigit growth trio year obviously underscore everything think see price volume anticipate obviously competitor entering exactly sure elancos quattro expectation differentiated product mention taper get tapeworm flea actually control flea therefore really differentiated product abused good competitor obviously nexgard sure heavy promotional think strength honestly corporate account experience switching low people product unlikely someone entree going switch quite well retail auto ship think also protects u expect new competitor expand market seeing lot movement triple combo topicals collar etc look confident trio number look year regard question learned librela europe branded advertising librela europe overall advertising disease awareness encouraging people pet dog cat osteoarthritis pain bring vet seeing real impact disease awareness think long time pet owner product could turn encouraging new product go vet seen seeing really positive uplift directtoconsumer advertising even branded know want add thatwetteny joseph chief financial officer look think covered kristin trio performing really well u face drug competition yous going pleased gaining patient share face competition think speaks lot talking power relationship strength label first market look initial heavy promotion happens new competitor come factor thinking see label see hold specific reaction confident ability grow continued growth franchise saying going see mid singledigit growth across trio welloperatorwell take next question nathan rich goldman sachs please go aheadnate rich goldman sachs analyst great good morning thanks question wanted ask derm franchise think talked mid high singledigit growth franchise overall guess specifically assuming headwind within guidance competitive entry likely occur apoquel year talk strategy maybe putting place defend market share product quick followup china could maybe frame type headwind expect china impact companion livestock side market thank youkristin peck chief executive officer sure take derm question think wetteny follow china question look saw strong growth quarter overall derm want underscore growth obviously understated given price looking pre priced buyin saw late look guidance mid high singledigit growth derm franchise expectation see competitor launch expect market continue expand grow talked million dog yous pruritus still million untreated dog million treated steroid sort overthecounter product strongly believe market continue expand look two product market seven year respectively million dog product product proven time safe efficacious trusted pet owner trusted vest seeing switch cytopoint build preference compliance pet owner vet competition expecting come filmcoated tablet look really focused investing apoquel chewable moving chewable pet owner really prefer successful europe quite focused yous also continuing look innovation short term longacting going defend franchise confident franchise guidance mid high single digit demonstrates believe continue grow market yous around world defend brand continue bring life cycle innovation space time grow share wetteny want take chinawetteny joseph chief financial officer yeah sure one point derm course mid high singledigit growth expectation laid guidance course across broad range expectation various scenario around competitor entry timing pricing etc play label course playing play confident ability grow franchise around decade space china consistent one think continue see sort broad economic situation remain expecting ignore improve least first half year also stronger comp similar second half little bit le first half still headwind first half continue see consumer confidence low swine price remaining fairly depressed consumption well factor course long term continue expect china strong growth market done exceptionally well u last decade near term expecting contribution growth fact see declining comp first half chinaoperatorthank take next question balaji prasad barclays please go aheadbalaji prasad barclays analyst hi good morning everyone thanks question couple firstly wanted understand currency dynamic better considering nearly basis point return revenue basis point eps going fx severe particular currency hurting mean general understanding billion plus billion export revenue dollar weakening thought impact would way around second question around fda letter zoetis received librela number wanted understand frequent normal kind letter animal health side issue fda found librelas promotion inclusion p value secondary end point current status regard communication fdakristin peck chief executive officer sure balaji take second question first let wetteny take see referencing letter back november honestly letter uneventful well addressed immediately resolved request clarification would talking request clarification promotional material made minor change promotional material represented statistical data concern well addressed modification accepted fda mean uncommon easily resolved last year minor issue wetteny want take second questionwetteny joseph chief financial officer yes sure currency dynamic forecast fx tend report see impact dollar continues strengthen number currency operate little bit disproportional effect see higher inflationary market like argentina follow argentina two really significant drop term fx rate versus dollar follow back ended last year december think back august little bit delayed effect clearly impact top line talked also little bit delayed effect look impact inventory receivables book time time collect greater impact see impact bottom line combination volume argentina brazil turkey pronounced relative percentage revenue given significantly value seeing play really across board look dollar ended year ended bit stronger saw throughout average yearoperatorthank take next question brandon vasquez william blair please go aheadbrandon vazquez william blair company analyst hi everyone thanks taking question first talk little bit pre priced buying quarter able quantify much headwind maybe talk expect headwind going forward guy still working followup maybe higher level anything pipeline kind product cycle management guy share u still spending lot money rd even next year look like may specific area get leverage rd line anything would able share u would helpful thank youwetteny joseph chief financial officer yes sure take first one kristin cover second one look always level pre priced buying exit year given price increase going would say compared prior year higher average reprice buying impact actively managed customer order term reprice buying exiting gave u really first underlying market strength momentum carried also would say quarter position walking january certainly better position say prior year actively manage always level numberskristin peck chief executive officer sure question regard rd obviously confident pipeline think innovative company animal health look exceeded market growth every year last year due innovation pipeline investing short medium long term animal health different human health really make difference look sort call like life cycle enhancement launched apical chewable significantly support key brand also looking pretty disruptive innovation well look sort short one threeyear term innovation excited really longacting talked lot investing medium long term really important new franchise well renal chronic kidney disease space looking cardiology looking oncology diabetes really important space unmet medical need animal health really excited tackle continuing invest behind diagnostics well behind livestock business looking new vaccine immunomodulators genetics business diverse pipeline diverse portfolio continuing invest behind remain confident thatoperatorthank take next question chris schott jp morgan please go aheadchris schott jpmorgan chase company analyst great thanks much question two latest vet visit growth know primary driver growth business targeting year trying get color underlying kind dynamic mostly still capacity macro dynamic color would appreciated second question coming back librela ex yous perspective penetrated market monoclonal point see largest opportunity growth market showing sense like second inning seventh inning ramp ex yous thankskristin peck chief executive officer sure mean starting first levered spoken many time business mean obviously inconsequential view historically historically see vet clinic visit time think really saying back normal really happening strong end market demand remains capacity issue yous think addressed stuff going auto ship retail online also supporting really sort view year look year although saw flat vet visit spot revenue revenue per visit really seeing really strong growth obviously overall revenue much correlated time given strength portfolio etc second question regard librela outside yous think still early inning really think see growth right product primarily used severe dog think getting moderate dog mean think obviously least somewhere mean say hip hurt right everyone know around reality osteoarthritis exists animal long living walk stair control pain early think critical think really trying change paradigm getting librela firstline use animal osteoarthritis pain getting moderate dog think continue grow market grow franchise know believe early inning across globe regard osteoarthritis pain librela certainly solensia still continue grow awareness osteoarthritis pain catsoperatorwell take next question stephen scala td cowen please go aheadunknown speaker chris steve two question first librela degree yous debt capacity constraint headwind longerterm treatment compliance regulatory path approval athome administrative formulation thank youkristin peck chief executive officer sure obviously making sure pet owner get monthly injection critical capacity certainly something quite focused think first visit injection certainly done vet tech think industry really focused partnering corporates abm lot people really think change paradigm vet vet tech clinic thing like believe solution really address vet capacity issue far globally way vet capacity issue yous issue global far affected growth key product second question regard home delivery want take onewetteny joseph chief financial officer yeah look think regulatory path really direction going term think make impact livestock innovation oa pain map across portfolio really important look ahead think longeracting formulation solensia librela direction help even though kristin said seeing significant impact term ability grow map think initial visit vet see pet injection beyond tech able etc varies bit see significant impact usoperatorwell take next question navann ty bnp paribas please go aheadnavann ty exane bnp paribas analyst hi good morning thanks taking question two one librela one trio first one librela continued investment remaining sgas addition current testing campaign clarification currently expect librela become potentially gross margin accretive trio help u explain switch mexico plus mostly bi home like large rather simparica trio see uptake bi younger dog puppy mostly thank youwetteny joseph chief financial officer take first one librela look course going making investment already started heard prepared commentary penetration level running expectation launched dtc librela already dtc across europe international market well look ahead make significant investment field force going back year half ago able leverage investment see incremental investment beyond drive expectation take advantage demand product gross margin picture mentioned earlier dilutive look particularly saw u outperform expectation librela right go librela margin actually accretive overall company margin leverage ish gross margin company librela gross margin would see innovative companion animal brand get beyond start see innovative level well company average hopefully help clarify point trio said seen really strong performance trio posting doubledigit growth grew yous continue gain patient share mean switching low product safe effication market almost four year pleased seeing know kristin want addkristin peck chief executive officer quite well topic yous specifically regard puppy mean puppy trio label want emphasize know original simparica mean really looking new start see lot puppy see lot conversion single dual agent customer triple combination certainly movement people topical oral lot way u continue gain market share product quite well puppy answer part questionoperatorthere seem question time turn call back speaker closing remarkskristin peck chief executive officer great thank much question honestly continued interest zoetis want undergo enduring strength human animal bond pet owner expectation humanquality healthcare pet need safe secure food supply underscore animal health industry essential durable remain confident strategy ongoing value proposition know colleague make difference every day everything support want reiterate expect grow faster market line grow operational revenue mid high single digit firmly committed investing innovative pipeline portfolio dtc program need support broadening building billiondollar franchise animal health industry resilient even time uncertainty poised navigate challenge portfolio diversity commitment exceptional customer experience operational excellence agility look forward keeping updated progress future call thanks must joining u today guy great dayoperatoroperator signoff duration minutescall participantssteve frank vice president investor relationskristin peck chief executive officerwetteny joseph chief financial officererin wright morgan stanley analystmike ryskin bank america merrill lynch analystjon block stifel financial corp analystdave westenberg piper sandler analystnate rich goldman sachs analystbalaji prasad barclays analystbrandon vazquez william blair company analystchris schott jpmorgan chase company analystunknown speakernavann ty exane bnp paribas analyst zts analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends zoetis motley fool disclosure policy